Arcutis Biotherapeutics (ARQT) – Investment Analysts’ Weekly Ratings Updates

Arcutis Biotherapeutics (NASDAQ: ARQT) has recently received a number of price target changes and ratings updates:

• 3/2/2026 – Arcutis Biotherapeutics had its price target lowered by Mizuho from $37.00 to $35.00. They now have an “outperform” rating on the stock.
• 2/27/2026 – Arcutis Biotherapeutics had its price target raised by Guggenheim from $34.00 to $35.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Arcutis Biotherapeutics had its price target raised by HC Wainwright from $30.00 to $34.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Arcutis Biotherapeutics had its price target raised by TD Cowen from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Arcutis Biotherapeutics had its price target raised by Needham & Company LLC from $31.00 to $36.00. They now have a “buy” rating on the stock.
• 2/14/2026 – Arcutis Biotherapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 1/26/2026 – Arcutis Biotherapeutics had its price target raised by Needham & Company LLC from $30.00 to $31.00. They now have a “buy” rating on the stock.
• 1/23/2026 – Arcutis Biotherapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.

Insiders Place Their Bets

In other news, insider Masaru Matsuda sold 8,733 shares of Arcutis Biotherapeutics stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $25.30, for a total value of $220,944.90. Following the completion of the sale, the insider owned 136,932 shares in the company, valued at $3,464,379.60. The trade was a 6.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Latha Vairavan sold 2,853 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $25.18, for a total transaction of $71,838.54. Following the transaction, the chief financial officer owned 87,754 shares in the company, valued at $2,209,645.72. This represents a 3.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 163,733 shares of company stock valued at $4,204,675 in the last 90 days. Company insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.